A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone[OCX 0191] (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion

Trial Profile

A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone[OCX 0191] (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2013

At a glance

  • Drugs OCX 191 (Primary)
  • Indications Cancer; Colorectal cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Jan 2008 Status changed from in progress to completed.
    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top